Biodexa's mtx110 shows promise in extending life expectancy against aggressive brain cancers

Topline results for progression-free survival expected in q2 2024 cardiff, uk / accesswire / march 28, 2024 / biodexa pharmaceuticals (nasdaq:bdrx) ("biodexa"), an acquisition-focused biopharmaceutical company, is developing mtx110 for the treatment of diffuse midline glioma (dmg) in pediatric patients and for recurrent glioblastoma (rgbm) in adults; two aggressive brain cancers with universally poor prognoses. the company says early trials of mtx110 in both cancers show promise in extending survival rates beyond those reported in previously published studies.
BDRX Ratings Summary
BDRX Quant Ranking